AKT1 and hepatocellular carcinoma: We have previously demonstrated that the Akt pathway is highly activated in sorafenib-resistant HCC (SR-HCC) cells and the inhibition of Akt could reverse this resistance by switching autophagy from a cytoprotective role to a death-promoting mechanism [6].